# Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer

> **NCT07706179** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Wisconsin, Madison** · enrollment: 10 (estimated)

## Conditions studied

- HR+/HER2+ Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Alisertib

## Key facts

- **NCT ID:** NCT07706179
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07706179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07706179, "Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07706179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*